1. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
- Author
-
C.B. Lambalk, A. Obruca, J.N. Hugues, J.L. Pouly, D.M. Braat, J.C. Sage, J.A.F. Huirne, A.C.D. van Loenen, Céline Pirard, and F. Fischl
- Subjects
Adult ,medicine.medical_specialty ,Randomization ,Adolescent ,medicine.medical_treatment ,Fertilization in Vitro ,Hormone antagonist ,Buserelin ,Intracytoplasmic sperm injection ,law.invention ,Gonadotropin-Releasing Hormone ,Hormone Antagonists ,Ovarian Follicle ,Ovulation Induction ,Randomized controlled trial ,Pregnancy ,law ,Oral administration ,Humans ,Medicine ,Sperm Injections, Intracytoplasmic ,Gynecology ,Endocrinology and reproduction [UMCN 5.2] ,business.industry ,Rehabilitation ,Effective Hospital Care [EBP 2] ,Obstetrics and Gynecology ,Human Reproduction [NCEBP 12] ,Regimen ,Reproductive Medicine ,Oocytes ,Female ,Ovulation induction ,business ,Contraceptives, Oral ,medicine.drug - Abstract
Item does not contain fulltext BACKGROUND: The aim of this study was to assess the non-inferiority of an oral contraceptive (OC)-pretreated cetrorelix regimen and a buserelin regimen in IVF/ICSI patients treated with r-hFSH in terms of total number of oocytes retrieved. METHODS: Multicentre, randomized study. One hundred and eighty two patients were randomized to receive cetrorelix with OC pretreatment (n = 91) or to receive buserelin (n = 91). The cetrorelix group started with daily OCs on cycle day 5 and continued for 21-28 days. Cetrorelix (0.25 mg) was given daily from stimulation day 6 up to and including the day of r-hCG administration. The buserelin group started with buserelin (500 microg/day) for at least 10 days until down-regulation was achieved, after which the dose was reduced to daily 200 microg up to and including the day of r-hCG administration. r-hFSH was started in both groups on a Friday, in the cetrorelix group 5 days after the last OC pill intake. Both regimens were followed by a standard IVF or ICSI procedure. The primary efficacy endpoint was the number of oocytes retrieved per patient. RESULTS: Number of oocytes, cancellation rates, r-hFSH requirements, number of oocyte retrievals during the weekend or public holiday and number of pregnancies were similar in both groups. Both treatment regimens were well tolerated. CONCLUSIONS: Cetrorelix pretreated with OCs resulted in similar number of oocytes retrieved compared with a long buserelin protocol. Both regimens were well tolerated and allowed scheduling of the oocyte retrieval, with only small number of retrievals falling on a weekend or public holiday.
- Published
- 2006
- Full Text
- View/download PDF